tbuckley/cabot-search huggingface dataset:
Abstract 17885: Inter-vendor Concordance of Strain is Analogous to Ejection Fraction After Strain Standardization Initiative
Authors: Hong Yang, Nobuaki Fukuda, Sudhir Wahi, Hiroki Oe, Makoto Saito, James D Thomas, Thomas Marwick, Kazuaki Negishi
Journal: Circulation (2014)

Background:  Disagreement of strain measurements among different vendors has provided an obstacle to the clinical use of strain. A joint standardization task force between professional societies and industry was initiated to reduce inter-vendor variability of strain. Although feedback from this process has been used in software upgrades, little is known about the effects of efforts to improve conformity. We sought whether inter-vendor agreement for global longitudinal strain (GLS) has improved after standardization initiatives.   Methods:  82 subjects (55% male) prospectively underwent two sequential examinations using two ultrasound systems (Vivid E9 vs. iE33). GLS was calculated using proprietary software EchoPAC BT12 (E12) and BT13 (E13) versus QLAB 8 (Q8), QLAB 9 (Q9) and QLAB 10 (Q10). Differences in GLS were evaluated with Bland-Altman plots. Coefficients of variation (CVs) were compared using Friedman test and compared with CVs of LV volumes and ejection fraction (EF).   Results:  The study population had wide ranges of age (18-95, mean 52±20.3 years) and body mass index (16-43, mean 25±6 kg/m2). Their LVEF was 58±12 % (14 -72%). Between-vendor differences in GLS showed larger CVs in the comparisons among pre-standardization software versions (Q8 vs E12 and E13) than those from post-standardization (Q9 and Q10 versus E12 and E13) (p   Conclusion:  Subsequent to the joint standardization task force, there has been improvement in between-vendor concordance in GLS, the variability of which is now analogous to that of LVEF. The removal of concerns about measurement variability should allow wider use of GLS.
Abstract 16526: Nanoparticle-mediated Targeting of Endothelial mir92a-PPAP2B Signaling Axis in Atherosclerosis
Authors: Congqing Wu, Lorraine Leon, Eun Ji Chung, Matthew Tirrell, Yun Fang
Journal: Circulation (2015)

Introduction: Atherosclerosis develops preferentially at arterial sites where endothelia are activated by local disturbed hemodynamics. We have recently demonstrated that disturbed flow suppresses PhosPhatidic-Acid-Phosphatase-type-2B (PPAP2B), an integral membrane protein also known as Lipid Phosphate Phosphatase (LPP3) that inactivates lysophosphatidic acid (LPA) and is implicated in coronary artery disease (CAD) by genome-wide association studies. Reduced PPAP2B was detected in athero-susceptible arterial sites exposed to disturbed flow in mice, swine and humans, resulting from elevated miR-92a. PPAP2B inhibition drives the inflammatory and permeable endothelial phenotype by activating LPA-stimulated signalings. Expression quantitative trait locus (eQTL) mapping demonstrated PPAP2B CAD risk allele is not linked to PPAP2B expression in various human tissues but significantly associated with reduced PPAP2B in human aortic endothelial cells (HAEC). Hypothesis: Given the critical role of PPAP2B in mediating the athero-resistant endothelial phenotype, we test the hypothesis that miR-92a inhibition that elevates PPAP2B can promote vascular health and alleviate atherosclerotic burdens. Novel nanoparticles are designed to spatially target dysfunctional endothelia and deliver miR-92a inhibitors. Methods: Polyelectrolyte complex micelles were engineered to encapsulate charged nucleic acids (miR-92a inhibitors) forming a core by neutralizing their charge. Valine-Histidine-Proline-Lysine-Glutamine-Histidine-Arginine (VHPKQHR), which was identified via phage display and binds vascular endothelial cells through the vascular cell adhesion molecule-1 (VCAM-1), was incorporated to the miRNA inhibitor-containing polyelectrolyte complex micelles to target inflammatory endothelia and facilitate the cellular uptake. Results and Conclusions: We have successfully engineered lesion-targeting polyelectrolyte complex micelles as an innovative delivery system for therapeutic nucleotides and tested their effectiveness in inhibiting miR-92a signaling in vitro in HAEC. Moreover, miR-92a inhibitor-containing micelles significantly reduced the lesion size in ApoE(-/-) mouse model of atherosclerosis in vivo.
Radiation and the Cell&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: Paul S. Henshaw
Journal: JNCI Journal of the National Cancer Institute (1940)

Radiation and the Cell Get access Paul S. Henshaw Paul S. Henshaw research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 3, December 1940, Pages 277–290, https://doi.org/10.1093/jnci/1.3.277 Published: 01 December 1940
Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications
Authors: Jalal Mosayebi, Mehdi Kiyasatfar, Sophie Laurent
Journal: Advanced Healthcare Materials (2017)

Abstract In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
Authors: R.A. Hubner, L-T. Chen, C-P. Li, G. Bodoky, A. Dean, K-H. Lee, D. Cunningham, J.T. Siveke, F.S. Braiteh, F.A. de Jong, B. Belanger, R. Walls, P.D. Mody, D.D. von Hoff, A. Wang-Gillam
Journal: Annals of Oncology (2017)
Change in the molecular profile of tumor tissues during treatment with trastuzumab, as analyzed by next-generation sequencing and immunohistochemistry: A multicenter prospective biomarker study on HER2-positive gastric cancer
Authors: N. Takahashi, S. Iwasa, T. Sawada, Y. Sasaki, H. Taniguchi, I. Oda, T. Honda, Y. Kojima, H. Hara, Y. Honma, A. Takashima, K. Kato, T. Hamaguchi, Y. Yamada
Journal: Annals of Oncology (2017)
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD
Authors: Marco Contoli, Alessia Pauletti, Maria Rita Rossi, Antonio Spanevello, Paolo Casolari, Andrea Marcellini, Giacomo Forini, Giulia Gnesini, Brunilda Marku, Neil Barnes, Andrea Rizzi, Giacomo Curradi, Gaetano Caramori, Paolo Morelli, Alberto Papi
Journal: European Respiratory Journal (2017)

Inhaled corticosteroid-containing medications reduce the frequency of COPD exacerbations (mainly infectious in origin) while paradoxically increasing the risk of other respiratory infections. The aim was to determine the effects of inhaled corticosteroids on airway microbial load in COPD patients and evaluate the influence of the underlying inflammatory profile on airway colonisation and microbiome.This is a proof-of-concept prospective, randomised, open-label, blinded endpoint study. Sixty patients with stable moderate COPD were randomised to receive one inhalation twice daily of either a combination of salmeterol 50 μg plus fluticasone propionate 500 μg or salmeterol 50 μg for 12 months. The primary outcome was the change of sputum bacterial loads over the course of treatment.Compared with salmeterol, 1-year treatment with salmeterol plus fluticasone was associated with a significant increase in sputum bacterial load (p=0.005), modification of sputum microbial composition and increased airway load of potentially pathogenic bacteria. The increased bacterial load was observed only in inhaled corticosteroid-treated patients with lower baseline sputum or blood eosinophil (≤2%) levels but not in patients with higher baseline eosinophils.Long-term inhaled corticosteroid treatment affects bacterial load in stable COPD. Lower eosinophil counts are associated with increased airway bacterial load.
Practical effectiveness efficacy and safety of nivolumab for advanced non-small cell lung cancer: A retrospective multicenter analysis
Authors: K. Kobayashi, I. Nakachi, K. Naoki, Y. Oyamada, M. Nakamura, T. Inoue, H. Tateno, F. Sakamaki, K. Sayama, T. Terashima, H. Koh, D. Arai, H. Yasuda, I. Kawada, K. Soejima, T. Betsuyaku
Journal: Annals of Oncology (2017)
GW28-e1150 The Experience of Successful Therapy with ECMO on the Patient Diagnosed as Fulminant Myocarditis with Multiple Organ Failure
Authors: Guitang Yang, Ding Jian, Guan Mingzi, Zhang Donghong, Gu Ruoxi, Sun Ying, Xu Guoqing, Peng Chengfei, Han Yaling, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Author's reply: Association of D222G substitution in haemagglutinin of 2009 pandemic influenza A (H1N1) with severe disease
Authors: A Kilander, R Rykkvin, S G Dudman, O Hungnes
Journal: Eurosurveillance (2010)

Preview this article: Author's reply: Association of D222G substitution in haemagglutinin of 2009 pandemic influenza A (H1N1) with severe disease, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/14/art19535-en-1.gif
GW28-e0956 The relationship between the contralateral collateral supply and myocardial viability of 18F-FDG PET/CT subtended by chronic total occluded coronary arteries
Authors: Wei Dong, Jianan Li, Xiantao Song, Xiaofen Xie, Jian Jiao, Quan Li, Yehong Zhang, Hongzhi Mi
Journal: Journal of the American College of Cardiology (2017)
Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.
Authors: Hartmut Goldschmidt, Ravi Vij, David Kuter, David Cella, Teresa Maria Zyczynski, Catherine C. Davis, Sergey Popov, Gordon Cook
Journal: Journal of Clinical Oncology (2016)

6621 Background: PREAMBLE (Prospective REsearch Assessment in multiple Myeloma: an oBservationaL Evaluation; NCT01838512) is an observational cohort study on the real-world effectiveness of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and combination therapy for RRMM. We report preliminary data on HCRU on the overall study population (US and Europe). Methods: Eligibility criteria: patients (pts) aged ≥ 18 y with RRMM ( ≥ 1 prior therapy) who initiated treatment with an IMiD, PI, or IMiD+PI 90 days prior/30 days after study enrollment. Pt data collected at each healthcare provider (HCP) visit included number of clinic/physician office visits, home healthcare, hospital outpatient and emergency room visits, and hospitalizations. Results: At data cut-off (Dec 2015), 764 treated pts (median age 68 y, 55% male) were enrolled; 599 (78%) relapsed, 161 (21%) refractory. Median time from diagnosis to index MM therapy was 41 mo (range 24–71). Of the 764 pts, 365 (48%) had prior transplantation experience. Forty-eight percent (n = 368) received an IMiD (lenalidomide 81%, n = 297), 45% (n = 347) received a PI (bortezomib 80%, n = 278), and 6% (n = 49) received an IMiD+PI. Majority of pts had 1 prior line of therapy (43%, n = 325), 27% (n = 203) had 2, 31% (n = 234) ≥ 3. Median follow-up: 15.1 mo (Q1–Q3 8–24). Median (Q1–Q3) number of HCP visits per relapsed pt during yr 1 was 4.5 (0–20) and 7 (0–20) per refractory pt. Median (Q1–Q3) number of HCP visits in Yrs 2 and 3 were 2 (0–12). Of 6804 total HCP visits, 3017 (44%) were hospital outpatients, 2779 (41%) clinic/physician, 371 (6%) hospitalizations. The main reason for visit (90%, 6143/6804) and hospitalization (66%, 276/417) was management of MM and its sequelae. The overall number of HCP visits and hospitalizations for management of treatment-related AEs was 9% (619/6804) and 33% (137/417), respectively. Surgical interventions accounted for 0.6% (42/6804) of resource use. Conclusions: Routine management and disease progression continues to drive HCRU in MM, regardless of lines of prior therapy. Early use of novel therapies with potential to provide durable responses could improve management of MM and pt outcomes. Additional analyses to apply costs are ongoing. Clinical trial information: NCT01838512.
Attempts to Produce Anaphylaxis in Guinea Pigs with a Polysaccharide from &lt;italic&gt;Serratia Marcescens (Bacillus Prodigiosus)&lt;/italic&gt;&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: F. E. Franke
Journal: JNCI Journal of the National Cancer Institute (1944)

Attempts to Produce Anaphylaxis in Guinea Pigs with a Polysaccharide from Serratia Marcescens (Bacillus Prodigiosus) F. E. Franke F. E. Franke assistant professor of physiology St. Louis University School of Medicine2 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 3, December 1944, Pages 173–177, https://doi.org/10.1093/jnci/5.3.173 Published: 01 December 1944
Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): A retrospective analysis
Authors: L. Incorvaia, G. Badalamenti, E. Musso, I. de luca, A. Casarin, G.M. Assanto, A. Galvano, F. Passiglia, N. Barraco, B. Vincenzi, G. Grignani, M. Pantaleo, L. Gatto, S. Rizzo, D. Fanale, M. Castiglia, A. Guarini, A. Russo
Journal: Annals of Oncology (2017)
nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm
Authors: C. Gridelli, M. McCleod, D. Morgensztern, D.B. Daniel, R. Page, T. Wehler, O. Juan, B. Levy, A. Ardizzoni, T. Berry, T. Chen, N. Trunova, R. Jotte
Journal: Annals of Oncology (2017)
Gene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC
Authors: R. Deurloo, N. Colombo, C. Mendiola, F. Selle, J. Korach, M.Z. Oestergaard, M. Bylesjo, H-J. Urban, Y. Ghazi, A. Oza
Journal: Annals of Oncology (2017)
Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer.
Authors: Enrique Luis Roca, Yuriy Vinnyk, Igor Bondarenko, Yaroslav V. Shparyk, Giovanni Mendonca Bariani, Kathia Abdalla, Fábio Franke, Felipe Cruz, Alvaro Romera, Sulabhchandra Bhamare, Suresh Sudalaiandi, Vikas S. Ostwal, Pradeep Shah, Sajeed Rahuman, Antonio Cubillo, Camino Huerga, Alexandra Paravisini, Francisco Javier Fernandez, Susana Millan
Journal: Journal of Clinical Oncology (2017)

e14065 Background: BEVZ92 has being developed as a proposed biosimilar approved reference medicine product (RMP). BEVZ92 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to RMP. The aim of this study was to demonstrate pharmacokinetics (PK) similarity of BEVZ92 to RMP, in combination in combination with FOLFOX or FOLFIRI, as first-line treatment in patients with mCRC (NCT02069704). Methods: PK analysis for multiple dose studies was conducted, as per guidelines, measuring the total exposure area under the concentration-time profile (AUC 0-336 ) at cycle 1, and to the end of the dosing interval at steady-state (AUC ss ) at cycle 7. PK similarity was achieved if 90% confidence interval (CI) for the test-to-reference ratios of AUC 0-336h and AUC ss were within 80.00–125.00% bioequivalence acceptance window. Secondary endpoints included other PK parameters, safety profile, immunogenicity and objective response rate (ORR). Results: A total of 142 patients were randomized and treated. Bevacizumab serum concentrations showed a ratio (90% CI) of geometric means for BEVZ92 and RMP were 99.4% (90.5%-109%) and 100% (90.2%–112%) for AUC 0-336h and AUC ss , respectively. All secondary PK endpoints which include C max , C trough , T max , t 1/2 , Kel, CL, Vd, and RA-AUC were also similar between the two arms. The ORR was 45% (95% CI, 33% to 57%) for BEVZ92, and 52% (95% CI, 40% to 64%) for RMP. Immunogenicity results showed a low incidence in the anti-drug antibodies de novo development and similar between both arms. Safety profile in terms of nature, frequency and severity was similar to the RMP and according to what is expected given the underlying disease and concurrent use of chemotherapy. Conclusions: These study results confirm the bioequivalence of BEVZ92 and the RMP in a real and common clinical setting, and translates the high similarity demonstrated in the in vitro and in vivo characterization into the clinical outcomes such as efficacy, immunogenicity and safety profile. Clinical trial information: NCT02069704.
Abstract 13815: Predictions of Wall-shear Stress on the Bicuspid Aortic Valves Using Three-dimensional Fluid-structure Interaction Models
Authors: Kai Cao, Philippe Sucosky
Journal: Circulation (2014)

INTRODUCTION:  The bicuspid aortic valve (BAV) is associated with a high prevalence of calcific aortic valve disease. Although abnormal hemodynamics has been proposed as potential pathogenic contributor, the native BAV hemodynamic stresses remain largely unknown. The objective of the present study was to characterize the regional wall shear stress (WSS) abnormalities on BAV leaflets using three-dimensional (3D) fluid-structure interaction (FSI) modeling.   METHODS:  The normal tricuspid aortic valve (TAV) model consisted of the aortic root, the aortic sinus and three identical compliant leaflets. The type-0 BAV consists of two equally-sized leaflets and two sinuses with no visible raphe while the type-1 BAV is characterized by asymmetry between a normal leaflet and a larger fused leaflet. The fully coupled FSI simulations were run in ANSYS by imposing a physiologic transvalvular pressure at the inlet of the fluid domain. Local leaflet WSS was characterized in terms of temporal shear magnitude (TSM).   RESULTS:  The TAV, type-0 BAV and type-1 BAV models successfully predicted leaflet and blood flow dynamics at a mean physiologic cardiac output of 4.2 L/min, 3.5 L/min and 3.2 L/min, respectively. The comparison of the flow in the three anatomies (Fig.1) suggests the existence of a central jet in the TAV and type-0 BAV but a jet skewed toward the smaller leaflet in the type-1 BAV model. The fibrosa (i.e., leaflet surface prone to calcification) WSS magnitudes in the type-0 BAV (TSM: 1.84 dyn/cm 2 ) and type-1 BAV (TSM: 2.05 dyn/cm 2 ) were found to be significantly higher than that in the TAV model (TSM: 0.55 dyn/cm 2 ).   CONCLUSION:  This study provides new evidence of the existence of abnormal hemodynamic stresses on BAV leaflets. The results provide new insights into the macro-scale valvular hemodynamics and are critical to the assessment of the hemodynamic theory of calcific aortic valve disease in BAV patients.  Figure 1. Snapshots of flow velocity field in TAV, type-0 and type-1 BAVs.
GW28-e1219 Radiofrequency catheter ablation for paroxysmal atrial fibrillation: over 3-year follow-up outcome
Authors: Yubing Wang, Yanping Xu, Zhiyu Ling, Weijie Chen, Li Su, Huaan Du, Peilin Xiao, Zengzhang Liu, Yuehui Yin
Journal: Journal of the American College of Cardiology (2017)
Abstract 11594: Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54
Authors: Marc P Bonaca, Stephen D Wiviott, David A Morrow, P. Gabriel Steg, Christian Hamm, Deepak L Bhatt, Robert F Storey, Julia Kuder, Sabina A Murphy, Giulia Magnani, Andrej Budaj, Pierre Theroux, José C Nicolau, Alexander Parkhomenko, José López-Sendón, Mikael Dellborg, Rafael Diaz, Frans Van de Werf, Ramón Corbalán, Eva C Jensen, Eugene Braunwald, Marc S Sabatine
Journal: Circulation (2015)

Objective: Ticagrelor reduced the risk of CV death, MI or stroke (MACE) in stable patients with prior MI in PEGASUS-TIMI 54. We investigated the efficacy of ticagrelor in reducing different subtypes and sizes of MI. Methods: MIs were adjudicated by the blinded TIMI Clinical Events Committee with definitions consistent with the Third Universal Definition of MI. Each MI was categorized by subtype and fold elevation of peak troponin (Tn) over the upper limit of normal (ULN). Results for both doses of ticagrelor were pooled in comparison to placebo. Results: A total of 1042 MIs occurred in the 21,162 randomized patients over a median follow up of 33 months. The majority (76%) of the MIs were spontaneous (Type 1), with demand MI (Type 2) and PCI-related (Type 4) accounting for 13% and 10% respectively (Figure Left); sudden death MI (Type 3) and CABG-related MI (Type 5) each accounted for &lt;1%. Using fold elevation in Tn, half of MIs (520, 50%) had a peak Tn ≥10x ULN and 21% of MIs (220) had a peak Tn ≥100x ULN (Figure Right). A total of 21% (224) were STEMI. Overall ticagrelor reduced MI at 3 yrs (4.47% vs 5.25%, HR 0.83, 95% CI 0.72 - 0.95, p=0.0055). The benefit was highly consistent among the different subtypes of MI (Figure left) and with increasing size of MI by fold elevation of Tn (Figure right) and for STEMI (HR 0.60, 95% CI 0.46 - 0.78, p=0.0002). Conclusion: In stable outpatients with a history of MI the majority of recurrent MI events are spontaneous and associated with a high biomarker elevation. Ticagrelor significantly reduces the incidence of MI consistently among different subtypes and biomarker sizes, with the greatest absolute reduction in spontaneous MIs, large MIs, and STEMI.
A biomimetic theranostic O 2 -meter for cancer targeted photodynamic therapy and phosphorescence imaging
Authors: Shi-Ying Li, Bo-Ru Xie, Hong Cheng, Chu-Xin Li, Ming-Kang Zhang, Wen-Xiu Qiu, Wen-Long Liu, Xiao-Shuang Wang, Xian-Zheng Zhang
Journal: Biomaterials (2017)